Basilea reports protocol amendment resulting in earlier

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study

BASEL, Switzerland, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its partner Astellas Pharma Inc. has filed an amendment to the phase 3 ACTIVE study protocol with the relevant health authorities and ethics committees. The study assesses the investigational antifungal isavuconazole in the treatment of candidemia and other invasive Candida infections.

In the protocol amendment, the targeted patient number will be reduced from 526 to 438 which will allow an earlier finalization of the study. A blinded assessment of the overall subject evaluability rate based on the available study data estimates a higher rate of evaluable patients than originally expected. This allows for a reduction in patient numbers while preserving sufficient statistical power for the primary objective of demonstrating non-inferiority in overall response rates at the end intravenous treatment between isavuconazole and caspofungin.

The protocol amendment is subject to regulatory and ethic committee approval.

Prof. Achim Kaufhold, Basilea's Chief Medical Officer, stated: "We are pleased that enrolment into the isavuconazole ACTIVE study may now be completed earlier than expected by early 2015 and topline data are anticipated for the second half of 2015, following completion of treatment and follow-up periods."

The phase 3 ACTIVE study is evaluating the safety and efficacy of intravenously (i.v.) and orally administered isavuconazole versus i.v. administered caspofungin followed by oral voriconazole in the treatment of candidemia and other invasive yeast infections caused by Candida spp. 1

Isavuconazole is currently under regulatory review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of invasive aspergillosis and mucormycosis in adults. In accordance with the FDA Prescription Drug User Fee Act (PDUFA), the FDA designated the date of March 8, 2015 for the completion of the U.S. New Drug Application review. The regulatory review of the European Marketing Authorization Application is anticipated to be completed by the fourth quarter of 2015.

About invasive candidiasis

Infections by Candida yeasts are serious invasive fungal infections and are associated with high morbidity and mortality. Estimates of the attributable mortality of Candida bloodstream infections (candidemia) range from 15% to 49%. 2, 3, 4

About isavuconazole

Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of life-threatening invasive fungal infections which predominantly occur in immunocompromised patients such as cancer patients undergoing chemotherapy.

Isavuconazole is currently under regulatory review by the FDA and the EMA for the treatment of invasive aspergillosis and mucormycosis in adults. It has European Union and U.S. orphan drug status for the treatment of invasive aspergillosis and mucormycosis. In addition, it was granted FDA fast-track status and designated a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis, mucormycosis and candidiasis under the U.S. Generating Antibiotics Incentives Now (GAIN) Act.

Isavuconazole is being co-developed with Astellas Pharma Inc. Basilea holds full rights to isavuconazole in markets outside of the U.S. and Canada where Astellas is the exclusive license holder.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company develops and commercializes innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations Investor Relations
Peer Nils Schröder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
media_relations@basilea.com
Barbara Zink, PhD, MBA
Head Corporate Development

+41 61 606 1233
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com .

References

1 Clinicaltrials.gov identifier: NCT00413218

2 J. Morgan et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infection Control and Hospital Epidemiology 2005 (26), 540-547

3 T. E. Zaoutis et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clinical Infectious Diseases 2005 (41), 1232-1239

4 O. Gudlaugsson et al. Attributable mortality of nosocomial candidemia, revisited. Clinical Infectious Diseases 2003 (37), 1172-1177

Press release (PDF) http://hugin.info/134390/R/1863336/653851.pdf

HUG#1863336

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 101

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 58

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 113

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 43

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 124

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies

Updated Category News Views 313

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies VICTOR Super Premium Pet Food, known for its dedication to high-quality pet nutrition, is proud to unveil a new line aimed specifically at canines with sensitive skin and stomach issues. The Sensitive Skin and Stomach line is designed to meet the dietary needs of both adult dogs and puppies, and will be...

Continue Reading
Exploring the Growth of the Pressure Monitoring Market

Updated Category News Views 181

The Expanding Pressure Monitoring Market This flourishing sector is gaining significant traction, reflecting a market valued at approximately US$13.63 billion in 2024, with a current rise to US$14.56 billion in 2025. The forecast indicates a notable compound annual growth rate (CAGR) of 8.3% from this point through 2032, culminating in an anticipated valuation of US$25.48...

Continue Reading
Citadel Credit Union Champions Community Engagement Initiatives

Updated Category News Views 636

Citadel Credit Union's Commitment to Community Support Citadel Credit Union is dedicated to reaffirming its commitment to its members and the surrounding region through an innovative approach to philanthropy. The organization has escalated its focus on community partnerships and employee-driven initiatives, making strides toward becoming a leader in promoting meaningful...

Continue Reading
TRIMEDX Bolsters Leadership with New Chief Data & AI Officer

Updated Category News Views 163

TRIMEDX Elevates Leadership with a Visionary Hire Indianapolis—TRIMEDX, a leading name in independent clinical asset management, is taking substantial strides in enhancing its technological offerings. The company has recently welcomed Srilekha Akula as its Chief Data & AI Officer. Her arrival marks a pivotal moment in TRIMEDX's journey, aimed at fostering innovation and...

Continue Reading
Exploring the Leadership of Ford as a Dividend Powerhouse

Updated Category News Views 170

Ford Motor Company (NYSE: F) has been a staple name in the automotive sector, but it’s got some serious hurdles to jump over. The stock price took a 12% nosedive over the past year, and while that might raise eyebrows, it also sets the stage for potential dividend plays. The price-to-earnings ratio is sitting pretty low at 11—sounds tempting for those looking at...

Continue Reading